



5 April 2019

(19-2178)

Page: 1/2

**Council for Trade-Related Aspects  
of Intellectual Property Rights**

Original: French

**NOTIFICATION OF LAWS AND REGULATIONS UNDER  
ARTICLE 63.2 OF THE TRIPS AGREEMENT**

CANADA: BILL C-30 (AN ACT TO IMPLEMENT THE COMPREHENSIVE ECONOMIC AND  
TRADE AGREEMENT BETWEEN CANADA AND THE EUROPEAN UNION AND ITS  
MEMBER STATES AND TO PROVIDE FOR CERTAIN OTHER MEASURES)

*Revision<sup>1</sup>*

<b>Notifying Member</b>	CANADA
-------------------------	--------

**Details of the notified legal text**

<b>Title</b>	Bill C-30 (An Act to implement the Comprehensive Economic and Trade Agreement between Canada and the European Union and its member States and to provide for certain other measures)
<b>Subject matter</b>	Patents (including plant variety protection)
<b>Nature of notification</b>	<input checked="" type="checkbox"/> Main dedicated intellectual property law or regulation <input type="checkbox"/> Other law or regulation
<b>Link to legal text</b>	<a href="https://members.wto.org/crnattachments/2018/IP/CAN/18_3274_00_e.PDF">https://members.wto.org/crnattachments/2018/IP/CAN/18_3274_00_e.PDF</a>
<b>Notification status</b>	<input type="checkbox"/> First notification <input checked="" type="checkbox"/> Amendment or revision to notified legal text <input type="checkbox"/> Replacement or consolidation of notified legal text(s)
<b>Previous notification(s) referred to</b>	<a href="#">IP/N/1/CAN/18, IP/N/1/CAN/P/13</a>

**Brief description of the notified legal text**

Bill C-30 amends the Patent Act, under new sections 104 to 134, to make available a Certificate of Supplementary Protection (CSP) for eligible new medicinal ingredients or new combinations of medicinal ingredients that are contained in human and veterinary drugs, following expiry of an eligible patent. The rights of a CSP match those of the patent as they apply to a medicinal ingredient or combination in a drug, with a few exceptions.

Bill C-30 also amends section 55.2(4) of the Patent Act to allow the Governor in Council to make regulations that will ensure that disputes brought under the Patented Medicines (Notice of Compliance) Regulations, which constitute Canada's pharmaceutical patent linkage regime, provides litigants with an equivalent and effective right of appeal.

<sup>1</sup> In French only. This revision is being circulated to announce a correction. Please consult the "Other information" section for more information.

<b>Language(s) of notified legal text</b>	English and French
<b>Entry into force</b>	21 September 2017; Bill C-30 received Royal Assent on 16 May 2017, and entered into force on 21 September 2017.
<b>Other date</b>	Adoption 16 May 2017

**Notification details**

<b>Submission date of notification</b>	20 June 2018
<b>Other information</b>	This revision is being circulated to correct some typological errors that occurred in the brief description of the notification, in particular the reference to Article "55.2(5)", which has been replaced with Article "55.2(4)" (see document IP/N/1/CAN/P/13). The Law itself has not been modified.
<b>Agency or authority responsible</b>	Innovation, Science and Economic Development Patent Policy Directorate  235 Queen Street Ottawa, Ontario K1A 0H5 Canada Telephone: 343-291-2686